Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy

Cancer Medicine

Volumn 5, Issue 9, 2016, Pages 2350-2358

  Exner, Ruth ^a   Sachet, Monika ^a   Arnold, Tobias ^a   Zinn Zinnenburg, Mercedes ^a   Michlmayr, Anna ^a   Dubsky, Peter ^a   Bartsch, Rupert ^a   Steger, Guenther ^a   Gnant, Michael ^a   Bergmann, Michael ^a   Bachleitner Hofmann, Thomas ^a   Oehler, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; chemotherapy; high mobility group box 1 protein; immunogenic cell death; prognostic marker

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIRUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 84991108279     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.827     Document Type: Article

References (39)

1. Mamounas, E. P. 2015. Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann. Surg. Oncol. 22:1425–1433.
2. Kaufmann, M., G. von Minckwitz, H. D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, et al. 2007. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann. Oncol. 18:1927–1934.
3. Kaufmann, M. 2006. Recommendations from an International Expert Panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 24:1940–1949.
4. Krysko, D. V., K. D'Herde, and P. Vandenabeele. 2006. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 11:1709–1726.
5. Tesniere, A., T. Panaretakis, O. Kepp, L. Apetoh, F. Ghiringhelli, L. Zitvogel, et al. 2008. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15:3–12.
6. Zitvogel, L., O. Kepp, L. Senovilla, L. Menger, N. Chaput, and G. Kroemer. 2010. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin. Cancer Res. 16:3100–3104.
7. Krysko, D. V., A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele. 2012. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12:860–875.
8. Zitvogel, L., L. Apetoh, F. Ghiringhelli, and G. Kroemer. 2008. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8:59–73.
9. Kepp, O., L. Senovilla, I. Vitale, E. Vacchelli, S. Adjemian, P. Agostinis, et al. 2014. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3:1–19.
10. Lotze, M. T., and K. J. Tracey. 2005. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5:331–342.
11. Kim, S., S. Y. Kim, J. P. Pribis, M. Lotze, K. P. Mollen, R. Shapiro, et al. 2013. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol. Med. 19:88–98.
12. Levy, R. M., K. P. Mollen, J. M. Prince, D. J. Kaczorowski, R. Vallabhaneni, S. Liu, et al. 2007. Systemic inflammation and remote organ injury following trauma require HMGB1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:R1538–R1544.
13. Tang, D., R. Kang, H. J. III Zeh, and M. T. Lotze. 2010. High-mobility group box 1 and cancer. Biochim. Biophys. Acta 1799:131–140.
14. Sunden-Cullberg, J., A. Norrby-Teglund, A. Rouhiainen, H. Rauvala, G. Herman, K. J. Tracey, et al. 2005. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock*. Crit. Care Med. 33:564–573.
15. Schierbeck, H., R. Pullerits, C. Pruunsild, M. Fischer, D. Holzinger, Å. Laestadius, et al. 2013. HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration. J. Rheumatol. 40:1604–1613.
16. Craig, D. G., P. Lee, E. A. Pryde, G. S. Masterton, P. C. Hayes, and K. J. Simpson. 2011. Circulating apoptotic and necrotic cell death markers in patients with acute liver injury. Liver Int. 31:1127–1136.
17. Arnold, T., A. Michlmayr, S. Baumann, C. Burghuber, U. Pluschnig, R. Bartsch, et al. 2013. Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur. J. Clin. Invest. 43:286–291.
18. Steger, G. G., R. Greil, A. Lang, M. Rudas, F. Fitzal, B. Mlineritsch, et al. 2014. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Ann. Oncol. 25:366–371.
19. Miller, A. B., B. Hoogstraten, M. Staquet, and A. Winkler. 1981. Reporting results of cancer treatment. Cancer 47:207–214.
20. Berruti, A., M. P. Brizzi, D. Generali, M. Ardine, L. Dogliotti, P. Bruzzi, et al. 2008. Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. Oncologist 13:1137–1148.
21. Dupont, W. D., and W. D. Plummer. 1990. Power and sample size calculations. A review and computer program. Control Clin. Trials 11:116–128.
22. McShane, L. M., D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, and G. M. Clark. 2006. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 100:229–235.
23. Tabata, C., E. Shibata, R. Tabata, S. Kanemura, K. Mikami, Y. Nogi, et al. 2013. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 13:205.
24. Fahmueller, Y. N., D. Nagel, R. T. Hoffmann, K. Tatsch, T. Jakobs, P. Stieber, et al. 2013. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int. J. Cancer 132:2349–2358.
25. Stoetzer, O. J., D. M. I. Fersching, C. Salat, O. Steinkohl, C. J. Gabka, U. Hamann, et al. 2013. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumor Biol. 34:81–90.
26. Wittwer, C., S. Boeck, V. Heinemann, M. Haas, P. Stieber, D. Nagel, et al. 2013. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int. J. Cancer 133:2619–2630.
27. Kohles, N., D. Nagel, D. Jüngst, P. Stieber, and S. Holdenrieder. 2012. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumor Biol. 33:2401–2409.
28. Tang, D., T. R. Billiar, and M. T. Lotze. 2012. A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol. Med. 18:1360–1362.
29. Antoine, D. J., R. E. Jenkins, J. W. Dear, D. P. Williams, M. R. McGill, M. R. Sharpe, et al. 2012. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J. Hepatol. 56:1070–1079.
30. Nolte, M. A., R. W. van Olffen, K. P. J. M. van Gisbergen, and R. A. W. van Lier. 2009. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 229:216–231.
31. van de Ven, K., and J. Borst. 2015. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy 7:655–667.
32. Goto, N., H. Tsurumi, M. Takemura, N. Kanemura, S. Kasahara, T. Hara, et al. 2012. Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Leuk. Lymphoma 53:1494–1500.
33. Kakoulidou, M., R. Giscombe, X. Zhao, A. K. Lefvert, and X. Wang. 2007. Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation. Scand. J. Immunol. 66:529–537.
34. Haile, S. T., S. P. Dalal, V. Clements, K. Tamada, and S. Ostrand-Rosenberg. 2013. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J. Immunol. 191:2829–2836.
35. Huber, S., R. Hoffmann, F. Muskens, and D. Voehringer. 2010. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood 116:3311–3320.
36. He, X.-H., Y. Liu, L.-H. Xu, and Y.-Y. Zeng. 2004. Cloning and identification of two novel splice variants of human PD-L2. Acta Biochim. Biophys. Sin. (Shanghai) 36:284–289.
37. Liedtke, C., C. Mazouni, K. R. Hess, F. André, A. Tordai, J. A. Mejia, et al. 2008. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26:1275–1281.
38. Cortazar, P., L. Zhang, M. Untch, K. Mehta, J. P. Costantino, N. Wolmark, et al. 2014. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172.
39. Berruti, A., V. Amoroso, F. Gallo, V. Bertaglia, E. Simoncini, R. Pedersini, et al. 2014. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J. Clin. Oncol. 32:3883–3891.